Stocktoria
Vivani Medical, Inc. VANI
Vivani Medical, Inc. (VANI) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.287 |
| Retained earnings / assets | -3.771 |
| EBIT / assets | -0.7 |
| Equity / liabilities | 0.665 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VANI | Vivani Medical, Inc. | 1/9 | -14.41 | — | — |
| MDT | Medtronic plc | 7/9 | 3.76 | 21.6 | +8.4% |
| ITGR | Integer Holdings Corp | 6/9 | 3.52 | 31 | +8% |
| MASI | MASIMO CORP | 7/9 | 6.71 | — | +9.4% |
| LIVN | LivaNova PLC | 4/9 | 0.72 | — | +10.7% |
| CNMD | CONMED Corp | 5/9 | 2.97 | 23 | +5.2% |
| TMDX | TransMedics Group, Inc. | 6/9 | 4.04 | 12.4 | +37.1% |
About Vivani Medical, Inc.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
FAQ
Is VANI financially healthy?
Vivani Medical, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does VANI pay a dividend?
No, Vivani Medical, Inc. does not currently pay a dividend.
How profitable is VANI?
In FY2025, Vivani Medical, Inc. had a return on equity of -169.2%.
What is the analyst price target for VANI?
The average Wall-Street price target for Vivani Medical, Inc. is $3.83, about 179.8% above the recent price, from 3 analysts (consensus: strong buy).
Is VANI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Vivani Medical, Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.